Privia Health Group (NASDAQ:PRVA) CFO Sells $597,891.61 in Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 23,887 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $25.03, for a total transaction of $597,891.61. Following the completion of the sale, the chief financial officer owned 172,909 shares in the company, valued at $4,327,912.27. This represents a 12.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Privia Health Group Price Performance

Shares of NASDAQ PRVA opened at $23.94 on Friday. Privia Health Group, Inc. has a 1 year low of $18.77 and a 1 year high of $26.51. The company has a 50 day simple moving average of $24.43 and a 200 day simple moving average of $22.82. The firm has a market cap of $2.94 billion, a PE ratio of 184.17, a price-to-earnings-growth ratio of 4.08 and a beta of 0.83.

Privia Health Group (NASDAQ:PRVA) last issued its quarterly earnings data on Tuesday, June 7th. The company reported $0.10 earnings per share (EPS) for the quarter. The company had revenue of $213.61 million during the quarter. Privia Health Group had a return on equity of 2.52% and a net margin of 0.89%. As a group, research analysts anticipate that Privia Health Group, Inc. will post 0.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on PRVA. BMO Capital Markets started coverage on shares of Privia Health Group in a research report on Thursday, November 13th. They set an “outperform” rating and a $30.00 price objective on the stock. Citigroup reaffirmed an “outperform” rating on shares of Privia Health Group in a research note on Friday, August 29th. Evercore ISI raised their price objective on Privia Health Group from $28.00 to $30.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Stephens reaffirmed an “overweight” rating and set a $32.00 target price on shares of Privia Health Group in a research report on Thursday, December 4th. Finally, Truist Financial reiterated a “buy” rating and issued a $31.00 target price (up from $30.00) on shares of Privia Health Group in a report on Monday, November 10th. Twelve analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Privia Health Group presently has an average rating of “Moderate Buy” and a consensus price target of $30.42.

Institutional Investors Weigh In On Privia Health Group

Several large investors have recently made changes to their positions in PRVA. Russell Investments Group Ltd. boosted its holdings in shares of Privia Health Group by 2,852.2% in the 1st quarter. Russell Investments Group Ltd. now owns 2,657 shares of the company’s stock worth $60,000 after buying an additional 2,567 shares during the last quarter. CWM LLC raised its position in Privia Health Group by 89.4% in the second quarter. CWM LLC now owns 3,416 shares of the company’s stock worth $79,000 after acquiring an additional 1,612 shares during the period. Canada Pension Plan Investment Board boosted its stake in Privia Health Group by 48.0% in the second quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock valued at $85,000 after acquiring an additional 1,200 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Privia Health Group during the 2nd quarter valued at approximately $113,000. Finally, Covestor Ltd increased its stake in shares of Privia Health Group by 39.8% during the 3rd quarter. Covestor Ltd now owns 5,824 shares of the company’s stock worth $145,000 after purchasing an additional 1,657 shares during the last quarter. 94.48% of the stock is owned by hedge funds and other institutional investors.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.